Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - November 2013


Drug-drug combinations made simple

06 Nov 2013 - 06 Nov 2013 - Webinar



Bookmark and Share


Date/Time: 6 November 2013, 4:00 PM CEST | 2:00 PM GMT | 10:00 AM EST | 7:00 AM PST

Drug screening for combinations or single agents can be demanding and tedious. At the Netherlands Cancer Institute Robotics and Screening Center (NRSC), potential drug combinations that either restore or enhance clinical response are selected based on large-scale genomic screening projects which combine genomic datasets including clinical data. The Institute’s HP D300 Digital Dispenser offers accurate, flexible and user-friendly experimental set-up for these combination studies, saving valuable time.

The NRSC uses an advanced technology platform to perform large-scale, high throughput screening projects with cell-based or biochemical assays. These screens enable researchers to identify novel targets for cancer therapy and understand the mechanism of action of novel drugs, as well as to identify resistance mechanisms and determine effective drug combinations for specific patient groups carrying defined genetic alterations.

In this presentation, the NRSC’s workflow for identification of drug combinations and follow-up drug synergy studies using the HP D300 will be presented.

About the speakers

Beijersbergen.gif
Roderick L. Beijersbergen, Associate Professor Division of Molecular Carcinogenesis and Head NKI Robotics and Screening Center.


Halonen.gif
Pasi Halonen, Post-doc Division of Molecular Carcinogenesis and NKI Robotics and Screening Center


Merlino.gif
Jessica Merlino, Product Manager HP D300, Tecan



Further information
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!